Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of acetylsalicylic acid and atorvastatin in castration-resistant prostate cancer
2017-004639-35Phase 3Active
- Sponsor
- Gustave Roussy
- Start
- Aug 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of atorvastatin and aspirin in castration-resistant prostate cancer (CRPC), sponsored by Gustave Roussy. Primary endpoint: Overall survival. Started Aug 2018; status: active.
02
Drugs
atorvastatinaspirin
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2017-004639-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004639-35.